{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-080962","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2026-07-07T12:10:51+00:00","discovered_at":"2026-07-07T12:15:00.561119+00:00","generated_at":"2026-07-07T12:15:15.700563+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Theriva Biologics gets Spanish regulator approval to start VIRAGE2 Phase 2a trial of VCN-01 in pancreatic cancer","bullets":["AEMPS authorized VIRAGE2, a Phase 2a trial evaluating at least 3 doses of VCN-01 given 2 months apart with gemcitabine/nab-paclitaxel in first-line metastatic PDAC.","VIRAGE2 builds on VIRAGE Phase 2b (112 patients) where 2 doses of VCN-01 3 months apart significantly improved overall survival, PFS, and duration of response vs. 1 dose or SoC alone.","EMA and FDA recognized improved survival with 2 doses and suggested more frequent dosing could improve outcomes.","Results will inform dosing regimen for a potential future pivotal Phase 3 trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-080962","json":"https://secwatch.observer/filing/0001104659-26-080962.json","markdown":"https://secwatch.observer/filing/0001104659-26-080962.md","text":"https://secwatch.observer/filing/0001104659-26-080962.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465926080962/0001104659-26-080962-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465926080962/tm2619846d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-07T12:15:15.700563+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}